Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/27/2008

outstanding at December 31, 2007.

Arena's 2007 Highlights

-- Initiated BLOSSOM and BLOOM-DM, the second and third Phase 3 pivotal

trials evaluating the efficacy and safety of Arena's lead drug

candidate, lorcaserin hydrochloride, or lorcaserin, for the treatment

of obesity. These one-year, double-blind, randomized and

placebo-controlled trials are expected to collectively enroll

approximately 3,750 overweight and obese patients. Consistent with

Arena's proposal, the US Food and Drug Administration, or FDA, has

allowed Arena to eliminate the requirement to perform

echocardiographic testing prior to enrolling patients in both BLOSSOM

and BLOOM-DM. This is different from the design of BLOOM, the initial

lorcaserin pivotal study, in which echocardiography was used to screen

for patients with FDA-defined valvulopathy, and certain other

echocardiographic abnormalities, and exclude those patients from

enrolling in the trial.

-- Completed a public offering of 11.0 million shares of common stock at

$9.91 per share, resulting in net proceeds to Arena of approximately

$103.2 million.

-- Announced positive preliminary results from Arena's Phase 2a clinical

trial of APD125 in patients with chronic insomnia. In this Phase 2a

clinical trial, APD125 significantly improved endpoints measuring

improvements in sleep maintenance with no observations of next day

cognitive impairment.

-- Reported that an independent Echocardiographic Safety Monitoring Board

found no reason to stop the ongoing pivotal Phase 3 lorcaserin BLOOM

trial following a planned review of unblinded echocardiograms

performed after patients completed six months of dosing in the trial.

The review confirmed that differences, if any, in the rates of
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... May 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... announced that it has priced an underwritten registered offering ... price of $9.00 per share, and granted the underwriters ... to an additional 585,000 shares of its common stock. ... million.  The offering is expected to close on May 6, ...
(Date:5/1/2015)... 1, 2015 Albany Molecular Research Inc. (NASDAQ: ... Marth , AMRI,s President and Chief Executive Officer, will ... Health Care Conference on Wednesday, May 13, 2015 at ... of the presentation can be accessed at AMRI,s Investor ... The webcast will be archived for 90 days following ...
(Date:4/30/2015)... , April 30, 2015   Tamir Biotechnology ... today an update on its Ebola antiviral therapy program. ... leading candidates, TMR004, is currently being evaluated and considered ... the battle against Ebola. During the first quarter of ... Leadership Meeting To Accelerate The Evaluation of Potential Treatments ...
(Date:4/30/2015)... The following is an open letter sent April ... Blood Corp (NYSE: CO ) from Jayhawk Capital. ... directors of China Cord Blood Corp (" China Cord ") ... share from Golden Meditech Holdings Co Ltd ("Golden Med"). Certainly, ... benefit Golden Med and Mr. Kam, the Chairman of both ...
Breaking Biology Technology:BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5
... Imaging Services to Unprecedented Number of ... Claustrophobic, Elderly and Bariatric Patients, MALVERN, Pa., Feb. ... become the first facility in the United,States to install ... Solutions (http://www.usa.siemens.com/healthcare ) -- the,MAGNETOM(R) Verio. Combining 3 ...
... Feb. 4 Cell,Genesys, Inc. (Nasdaq: CEGE ) ... executive officer of Cell Genesys, will present a,company update ... York, New,York, on Monday, February 11, 2008 at 11:00 ... presentation will be accessible through the,Investor Relations section of ...
... Centocor, Inc. announced today,that the Biologics License ... for review by the U.S. Food and Drug ... chronic moderate to severe plaque,psoriasis. Ustekinumab is a ... action that targets the cytokines interleukin-12 (IL-12) and,interleukin-23 ...
Cached Biology Technology:Johns Hopkins Bayview at Forefront of Expanding Access to MRI With First Install of Siemens New MAGNETOM Verio 2Johns Hopkins Bayview at Forefront of Expanding Access to MRI With First Install of Siemens New MAGNETOM Verio 3Cell Genesys to Present at the BIO CEO and Investor Conference 2Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA 2Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA 3
(Date:3/23/2015)... 23, 2015 SoundView Technology Group issues a new ... NXTD ) Wocket smart wallet. SoundView was one of the selected ... experience with the Wocket in multiple scenarios and outlets. ... and other retailers, making both debit and credit card payments.  ... says, "If the company meets their plans in 2015, it ...
(Date:3/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... CNBC television starting March 30 th . ... New York markets. ... excited about our new ad campaign following the recent initial ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... is one of the products featured in 2015 "I ... at 11:00 PM EST on the DIY Network.   ... Las Vegas , site of the 2015 ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... received a $3.3 million contract from the U.S. Defense Advanced ... be so soft and squishy that they will be able ... morph back into something 10 times larger, and ultimately biodegrade. ... conduct dangerous or difficult operations are clear, and the U.S. ...
... essential hypertension also develop diabetes and other complications in ... discovered a common molecular mechanism in a strain of ... in mammals. , The bioengineering researchers at UC San ... drug developed for unrelated purposes in humans was effective ...
... Crohn,s disease researchers has combined data from three ... associated with the inflammatory bowel disorder, bringing the ... Several of these are involved with the immune ... that disruptions in a process called autophagy may ...
Cached Biology News:Tufts to develop morphing 'chemical robots' 2Tufts to develop morphing 'chemical robots' 3A single mechanism for hypertension, insulin resistance and immune suppression 2A single mechanism for hypertension, insulin resistance and immune suppression 3A single mechanism for hypertension, insulin resistance and immune suppression 4International team identifies 21 new genetic risk factors for Crohn's disease 2
... number is a new product number, ... number. If showing no availability yet, ... number (E6152) or contact customer service ... diam. 11.25 6.40 in. ...
... Analysis of large numbers of samples may ... which requires minimum operator attention. System control ... and interface CE 4900. The elegant, powerful ... Windows XP and Windows 98 and 2000., The ...
Mouse monoclonal antibody to QPCT - glutaminyl-peptide cyclotransferase (glutaminyl cyclase)...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z35,347-7) ...
Biology Products: